Ratislav Bahleda

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau et al. · Clinical Cancer Research · 2017 · 102 citations

Medicine, Oncology, Pharmacology +17

Tumour growth rates and RECIST criteria in early drug development

Carlos Gomez‐Roca, Serge Koscielny, Vincent Ribrag et al. · European Journal of Cancer · 2011 · 81 citations

Medicine, Oncology, Pharmacology +16

Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

Funda Meric‐Bernstam, Hendrik-Tobias Arkenau, Ben Tran et al. · Annals of Oncology · 2018 · 67 citations · Full text

Medicine, Oncology, Pharmacology +16

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety

Carlos Gomez‐Roca, Ludovic Lacroix, Christophe Massard et al. · Annals of Oncology · 2011 · 44 citations

Medicine, Biomedical Sciences, Experimental Design +9

Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147), a Pan-Class I PI3K Inhibitor, in Combination With Erlotinib in Patients With Solid Tumors

Jean‐Charles Soria, Patricia LoRusso, Ratislav Bahleda et al. · The Oncologist · 2015 · 37 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +15